Azienda Ospedaliera S Giovanni Addolorata

At Azienda Ospedaliera S Giovanni Addolorata in Rome, a major share of research focuses on neoplasms, especially non-small cell lung cancer, small cell lung cancer, colorectal cancer, breast cancer, and gastric cancer. These studies are designed to test new treatment options, improve survival outcomes, and refine care for patients with advanced or hard-to-treat cancers.

• Studies in lung cancer are evaluating targeted and immunotherapy-based approaches for EGFR, RET, KRAS, and HER2-driven disease.
• Hemic and lymphatic diseases research includes acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes, and lymphoma.
• Other oncology trials are exploring better treatment strategies for ovarian cancer, triple negative breast cancer, and colorectal cancer.

Overall, the site’s cancer program is centered on comparing new therapies with current standards to improve disease control, extend survival, and support more personalized treatment choices.

The site also conducts clinical research in cardiovascular diseases, including heart failure, acute myocardial infarction, and atherosclerotic cardiovascular disease. These trials aim to improve prevention and treatment of major heart and vascular events while identifying better ways to reduce complications.

• Research in heart failure is assessing supportive therapies for patients with ischemic heart disease.
• Studies in acute myocardial infarction and atherosclerosis are examining new approaches to lower cardiovascular risk and vascular damage.
• Some trials focus on preventing serious outcomes such as myocardial infarction, stroke, and urgent revascularization.

This area reflects a strong interest in both treatment effectiveness and long-term cardiovascular protection.

Research in digestive system diseases includes colorectal cancer, gastric cancer, and ulcerative colitis. The trials are aimed at improving disease control, testing new biologic and targeted therapies, and evaluating options for patients who need better symptom and survival outcomes.

• Colorectal cancer studies are looking at new targeted and immune-based combinations for advanced disease.
• Gastric cancer trials are assessing whether novel therapies can improve survival in previously untreated patients.
• Ulcerative colitis research is focused on helping patients achieve remission through new anti-inflammatory treatments.

These studies show a broad effort to advance care across both cancer and chronic inflammatory bowel disease.

The site includes clinical trials in eye diseases, particularly neurotrophic keratopathy. This research is centered on evaluating whether new ophthalmic treatments can improve healing, protect vision, and relieve symptoms in patients with this rare condition.

• Trials are assessing new approaches for neurotrophic keratopathy, a condition that can seriously affect the cornea and vision.
• The goal is to determine whether investigational eye treatments can offer better safety and symptom relief than current care.

This field adds an important non-oncology dimension to the site’s research portfolio.

In musculoskeletal diseases, the site is studying chronic low back pain. The main purpose is to test whether new pain-relief strategies can provide better symptom control and improve daily functioning for people living with persistent back pain.

• Research is focused on finding more effective options for chronic low back pain.
• The trials aim to compare new therapies with existing pain treatments to see which approach offers better relief.

This work supports the development of more practical and patient-friendly pain management options.

The Unità Clinica di Fase I di Oncologia, Ematologia, Medicina Nucleare contributes to studies that evaluate emerging diagnostic and therapeutic techniques across several disease areas. This includes research designed to better measure treatment response, refine patient selection, and support more precise care.

• Trials are examining whether new treatment combinations can improve efficacy and survival outcomes.
• Some studies focus on improving how patients are identified for specific therapies through better diagnostic markers.
• The site’s work also supports the development of more personalized treatment strategies in oncology and cardiology.

This research area connects the site’s clinical expertise with practical advances in how diseases are detected and managed.